Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation?
- First Online:
- Cite this article as:
- Ehrlich, J.R. & Dobrev, D. Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384: 109. doi:10.1007/s00210-011-0647-5
- 365 Downloads
Presently available drugs used for atrial fibrillation (AF) therapy have major limitations (moderate efficacy and increased risk of potentially life-threatening proarrhythmia), making new drug developments crucial. Novel drugs like the multichannel blocker dronedarone have the potential to convert AF to prevent AF-related stroke and to reduce cardiovascular morbidity and mortality, opening new directions for innovative antiarrhythmic options. Here we summarize mechanistic evidence for atrial-selective sodium channel block as anti-AF principle putting it into perspective to the work by Bogdan et al. 2011, which demonstrated stronger sodium current inhibition by dronedarone at depolarized potentials resulting in atrial selectivity. We also discuss pertinent facts about remodeling processes induced by and leading to AF which likely explain why pharmacological cardioversion is effective in very early stages of AF only.
Atrial selectivity of sodium channel block is a novel anti-AF approach that exploits atrial–ventricular differences in sodium current properties (more negative half-inactivation in atria) and in resting membrane potential (more positive in atria leaving a greater proportion of sodium channels in the inactivated state), leading to reduced atrial current availability at any given membrane potential. Therefore inactivated-state sodium channel blockers like dronedarone preferentially suppress atrial sodium currents, especially during rapid atrial rhythms like in AF. However, dronedarone less effectively terminates AF compared to amiodarone having only a moderate overall efficacy. Much more work is needed to precisely define the contribution of atrial-selective sodium current inhibition for dronedarone's overall anti-AF efficacy.
AF is an increasing health problem and is associated with substantial cardiovascular morbidity and mortality, with stroke representing the most critical complication. Presently available drugs used for therapy of AF (antiarrhythmic drugs and anticoagulants) have major limitations because of moderate efficacy and inherent risk of potentially life-threatening proarrhythmia or bleeding complications, making new drug developments crucial (Dobrev and Nattel 2010). Novel drugs like dronedarone have the potential to prevent AF-related stroke and to reduce cardiovascular morbidity and mortality (Hohnloser et al. 2009), opening a new avenue for innovative antiarrhythmic options.
In January 2010 dronedarone has been approved for the treatment of nonpersistent AF in Europe. It is an antiarrhythmic compound with rate- and rhythm-controlling properties, which has been developed as a structurally related, multichannel-blocking congener of amiodarone with a similarly broad spectrum of inhibitory actions on ion channels (Ehrlich and Nattel 2009). In the April issue of Naunyn-Schmiedeberg's Archive of Pharmacology, Bogdan and colleagues (2011) illustrate the mode of dronedarone action on sodium channels and identify a peculiar behavior of the substance to inhibit inactivated channels at more depolarized potentials more effectively, leading to atrial-selective sodium channel block. They demonstrate a similar behavior for calcium channels and find inhibitory action on hyperpolarization-activated currents (HCN4), which are critically involved in physiological sinus node automaticity.
Atrial-selective inhibition of sodium channels has previously been demonstrated for several antiarrhythmic agents (Burashnikov et al. 2007; Sicouri et al. 2010) and represents a property likely contributing to dronedarone's antiarrhythmic effect. Atrial sodium channel blockade leads to alterations of various biophysical parameters of sodium current (INa) that produce post-repolarization refractoriness without a major effect on action potential duration (APD). Post-repolarization refractoriness is defined as difference between effective refractory period (ERP) and APD75 in atria and difference between ERP and APD90 in ventricles. Ion channel inhibition is the conventional and still the most commonly applied principle for pharmacological treatment of cardiac arrhythmias. However, once the arrhythmia has occurred, AF by itself alters expression profile and biophysical behavior of cardiac ion channels (atrial electrical remodeling, see below), further enhancing the severity of the substrate and increasing the likelihood of AF to sustain (Nattel et al. 2008). The precise signaling that creates the arrhythmogenic substrate is incompletely understood, but is shown to involve Ca2+/calmodulin/calcineurin-dependent pathways (Dobrev and Nattel 2010). Likely because of the presence of such remodeling and the lack of an effect on related signaling, most antiarrhythmic drugs do neither arrest arrhythmia progression nor improve clinical outcome. Dronedarone is the first antiarrhythmic compound with clinically proven beneficial effect on morbidity and mortality in patients with AF (Hohnloser et al. 2009). It reduces AF recurrences after cardioversion and has low risk of relevant side effects. Owing to these issues, the recently published European guidelines for AF management have suggested dronedarone as first-line drug option for patients with nonpersistent AF (Camm et al. 2010). Despite the generally favorable safety profile, two recent cases of significant liver toxicity have been reported, which is not surprising based on structural similarities between dronedarone and amiodarone. Such significant toxicity would represent a great shortcoming to dronedarone if found to be causally related to the substance (http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm). Prospectively collected data in larger patients populations are clearly needed to further evaluate the safety profile of dronedarone in the different patient populations.
AF-related atrial electrical remodeling: why does it matter?
AF most commonly occurs in hearts that have been affected by and are modified through remodeling processes due to clinical conditions such as hypertension, coronary artery disease, or heart failure. Each disease entity causes specific atrial changes that contribute to development of diverse arrhythmia substrates (Schotten et al. 2011). Hypertension for instance increases atrial pressure and may lead to enhanced atrial fibrosis through angiotensin-mediated pathways with subsequently enhanced vulnerability to AF (Burstein and Nattel 2008). Heart failure is associated with a high prevalence of AF and leads to specific remodeling of the atria by promoting atrial fibrosis and impaired impulse conduction that maintain the arrhythmia (Ehrlich et al. 2002). Coronary artery disease may similarly enhance regional heterogeneity of impulse conduction in conjunction with enhanced automaticity (Nishida et al. 2011).
Mechanistically, AF is constituted by multiple reentrant or spiral waves (rotors) that lead to rapid and repetitive activation of the atria. The AF-associated electrical remodeling is characterized by shortened atrial APD, abbreviated atrial ERP with increased impulse conduction heterogeneity and conduction slowing that increase propensity to reentrant activity (Nattel et al. 2008). Wijffels et al. documented this self-perpetuating nature of AF in classical animal experiments through continuous re-induction of the arrhythmia via implanted pacemakers over a period of weeks (Wijffels et al. 1995). A similar behavior can be observed in many patients where AF progresses from the paroxysmal form to persistent AF (Jahangir et al. 2007), perhaps as a consequence of remodeling.
Several mechanisms contribute to AF persistence like ectopic activity (e.g., focal activation from specific sites such as great cardiac veins) or circles of macro-reentry, but the final common pathway of these processes is multiple wavelet reentry (Nattel et al. 2008). Maintenance of reentry critically depends on the presence of short wavelengths that can mathematically be represented as the product of conduction velocity times refractory period. If a cardiac disease reduces speed of impulse conduction by changing Na+ channel availability, increasing the amount of atrial fibrosis or altering intercellular communication through connexins, the wavelength is shortened and a substrate for reentry is created (Dhein et al. 2010). Similarly, if shortening of the ERP occurs by decreasing APD, the likelihood of reentry is increased (Dobrev 2006; Nattel et al. 2008). Enhanced anisotropic conduction and heterogeneity of repolarization are further associated with important disturbances in impulse propagation that may also lead to reentrant arrhythmias (Dhein et al. 2010). Consistent with these concepts, human APD is shortened with impaired rate adaptation during AF (Nattel et al. 2008). Atrial APD, and thus ERP, is determined by the balance between inward currents that depolarize and outward currents that repolarize atrial myocytes. Studies in AF patients showed that decreased L-type Ca2+ current (ICa,L; reduced depolarization power), increased inward rectifier K+ current IK1, and the constitutively active acetylcholine-dependent K+ current IK, ACh (enhanced repolarization power) are major contributors to APD shortening (Dobrev et al. 2005; Girmatsion et al. 2009; van Wagoner et al. 1999). In addition to fibrosis, slightly reduced peak sodium current (INa) amplitude but enhanced late sodium current, INa,late (Sossalla et al. 2010), and decreased connexin-40 expression (Gaborit et al. 2005) add to atrial conduction disturbances.
These AF-related changes in ion-channel properties alter the response to antiarrhythmic drugs, principally making AF more drug resistant. A poorer response of persistent AF has been shown for both Na+- and K+-channel blockers (Duytschaever et al. 2005). Accordingly, ion-channel remodeling by itself represents a potential antiarrhythmic drug target. Amiodarone treatment suppresses APD abbreviation during experimental AF (Shinagawa et al. 2003), whereas Ca2+-, K+-, and Na+-channel blockers are ineffective in that respect. Therefore, it has been assumed that prevention of ion-channel remodeling (suppression of ICa,L reduction) may contribute to amiodarone's superior efficacy in AF (Shinagawa et al. 2003). Inhibition of two-pore-domain TASK-1 leak channels, which are preferentially expressed in atria, may also contribute to amiodarone's anti-AF efficacy (Gierten et al. 2010). Whether suppression of ICa,L remodeling and inhibition of TASK-1 channels contribute to the antiarrhythmic effects of dronedarone is unknown.
Paradoxon of INa inhibition to terminate AF
The efficacy of sodium channel-blocking drugs for termination of AF is difficult to explain in the context of the classical multiple wavelet hypothesis outlined above. Such pharmacological agents should theoretically promote AF maintenance as they decrease conduction velocity by reducing INa and shortening wavelength. Paradoxically, and contrary to these predictions, many class I substances like flecainide and propafenone are effective in converting a large proportion of recent-onset AF (Capucci et al. 1994; Suttorp et al. 1989). These drugs are nonselective sodium channel blockers and additionally target other ion channels (Hwang et al. 2011; Voigt et al. 2010) involved in the remodeling process (Dobrev et al. 2005; Dobrev and Nattel 2010). This paradoxon might possibly be understood if we consider alternative concepts of functional reentry. According to spiral wave (rotor) theory (and in contrast to classical reentry concepts), atrial excitation during AF is viewed as spiral waves with rotors that meander through the atria with a gradient of excitability that makes activation in the center of a rotor slower than in the periphery (Jalife et al. 2002). Once atrial excitability is reduced by sodium channel blockade, the rotor frequency decreases because the radius of the spiral wave increases, thereby preventing rotor stabilization and enhancing the likelihood of AF termination (Kneller et al. 2001). Although this theory is appealing, the precise mechanism of AF termination by sodium channel block remains unclear. The higher efficacy of class I antiarrhythmic drugs like vernakalant in cardioverting recent-onset compared with persistent AF (Ehrlich and Nattel 2009) might result from the generally lower degree of atrial remodeling in recent-onset AF. Due to the more complex pathophysiology in persistent AF with progressive structural changes in both atria (structural remodeling), AF stabilization in such patients may depend on structural rather than ion-channel remodeling. Complex interaction patterns between myocytes and fibroblasts may lead to reentrant circuits that depend to a lesser extent on functional reentry determinants like properties of INa currents.
Is atrial-selective INa inhibition sufficient to terminate AF?
As mentioned above class I antiarrhythmic agents like flecainide and propafenone are effective and commonly used agents for pharmacological AF cardioversion and prevention of AF recurrence in patients with no or low-degree structural heart disease. However, since they may precipitate deleterious side effects in individuals with coronary artery disease, their clinical applicability is limited (Camm et al. 2010).
The paper by Bogdan et al. presents results of a combined in vivo and in vitro study regarding the effects of dronedarone on monophasic APs, peak INa, and ICa,L as well as heterologously expressed HCN4 channels (Bogdan et al. 2011). Through changes in holding potential, they documented a strong potential-dependent efficacy of INa blockade by dronedarone. For instance at −80 mV, dronedarone half-maximally inhibited INa with an IC50 of ∼0.7 μmol/L, while at −100 mV the substance was largely ineffective, with 10 μmol/L producing only ∼9% current inhibition. The authors extend these findings on INa to a similar observation with ICa,L. Here they calculated an IC50 of ∼0.4 μmol/L at −40 mV, while at −80 mV dronedarone inhibited only a minor portion of the current (∼20%). These findings are consistent with previously published observations in canines and extend these recent data by quantifying the relative effectiveness of dronedarone at various membrane potentials. Overall, these data point to an atrial-selective action of dronedarone on INa in vivo. However, acute dronedarone is still less effective than acute amiodarone at clinically relevant concentrations to terminate experimental AF (Burashnikov et al. 2010). Together with data on clinical efficacy of the substance to convert AF (Touboul et al. 2003), this suggests that atrial-specific sodium channel inhibition by dronedarone is by itself not sufficient for AF conversion.
It is difficult to directly extrapolate experimental findings obtained in animals or expression systems to human whole-heart physiology. In the present study, the authors utilized measurements of APs in pigs and studied ventricular guinea-pig cardiomyocytes, adding another potential confounder by comparing different species. It is very important to note that composition and characteristics of ion channels may differ substantially between species and between cardiac regions. As the authors correctly acknowledge, the molecular composition of atrial sodium channels might not be equal to that of sodium channels in ventricular myocardium. Nevertheless, the results presented in the paper by Bogdan et al. were intrinsically consistent and compatible with previous data suggesting a minor role of species-specific differences in this context (Bogdan et al. 2011).
In summary, the study of Bogdan et al. 2011 demonstrates atrial-selective INa inhibition by dronedarone that is likely to contribute to the substance's anti-AF efficacy and its limited proarrhythmic effects at the ventricular level. Further extensive work is needed to explore other mechanisms underlying the therapeutic value of dronedarone in AF and to more precisely define the contribution of atrial-selective INa inhibition for the drug's overall anti-AF efficacy.
The help of Moritz Toenne, BSc with artwork is gratefully acknowledged. Dr. Ehrlich received funding from the Deutsche Herzstiftung and Else-Kröner-Fresenius Stiftung. Dr. Dobrev's research is supported by the German Federal Ministry of Education and Research Atrial Fibrillation Competence Network (grant 01Gi0204), the Deutsche Forschungsgemeinschaft (Do 769/1-3), the European Union (European Network for Translational Research in Atrial Fibrillation, EUTRAF), and the Foundation Leducq (European-North American Atrial Fibrillation Research Alliance, ENAFRA).
Conflict of interest
Dr. Ehrlich has received lecture fees from Sanofi-Aventis. Dr. Dobrev reports no conflict of interest.